Form 4: Intuitive Surgical Director Alan Levy Executes Stock Option and Sells Shares Under 10b5-1 Trading Plan

Director Alan Levy exercised stock options and sold 2,000 shares of Intuitive Surgical (ISRG) common stock at an average price of $370.6988, while also selling 2,000 shares acquired through option exercise at $154.2367.

Summary

• On April 23, 2024, Alan J Levy, a director of Intuitive Surgical Inc (ISRG), executed a transaction involving the company's stock.
• Levy exercised a non-qualified stock option to acquire 2,000 shares of common stock at a price of $154.2367 per share.
• Concurrently, Levy sold 2,000 shares of common stock at a weighted average price of $370.6988 per share, with individual sales ranging from $369.38 to $371.98.
• These transactions were conducted under a pre-arranged trading plan complying with SEC Rule 10b5-1, which is set to expire on May 8, 2024.
• Following these transactions, Levy directly owns 25,319 shares of Intuitive Surgical.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors. It is common for executives to utilize 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and Form 4 filings are standard practice.
• The use of 10b5-1 trading plans is a widely accepted method for corporate insiders to sell shares without raising concerns about trading on non-public information.
• Comparing Alan Levy's transactions to those of other directors in similar companies (e.g., Medtronic, Stryker) would require analyzing their respective Form 4 filings and trading patterns.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director selling shares, but the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates